Revenue: As of FY2026 Q1, the actual value is USD 2.141 M, missing the estimate of USD 4.55 M.EPS: As of FY2026 Q1, the actual value is USD -2.04.EBIT: As of FY2026 Q1, the actual value is USD -5.475 M.<h4>Financial Performance for Three Months Ended March 31, 2026 vs. 2025</h4><h4>Revenue</h4>Total Revenue for Ekso Bionics Holdings, Inc. was $2,141 million in 2026, a decrease of $1,234 million (-37%) from $3,375 million in 2025, primarily due to lower volume of Enterprise Health device sales across the Americas, EMEA, and APAC regions . Device Revenue was $1,344 million in 2026, compared to $2,487 million in 2025 . Service and Support Revenue was $594 million in 2026, compared to $708 million in 2025 . Subscriptions Revenue was $68 million in 2026, compared to $87 million in 2025 . Parts and Other Revenue increased to $135 million in 2026 from $93 million in 2025 .<h4>Geographic Revenue</h4>Americas Revenue was $1,554 million in 2026, down from $1,800 million in 2025, with United States revenue at $1,533 million in 2026 compared to $1,783 million in 2025 . EMEA Revenue was $547 million in 2026, a decrease from $1,084 million in 2025, with France revenue at $207 million in 2026 compared to $422 million in 2025, and Italy revenue at $26 million in 2026 compared to $407 million in 2025 . APAC Revenue was $40 million in 2026, significantly down from $491 million in 2025 .<h4>Cost of Revenue and Gross Profit</h4>Cost of Revenue was $1,067 million in 2026, decreasing by $502 million (-32%) from $1,569 million in 2025 . Gross Profit was $1,074 million in 2026, a decrease of $732 million (-41%) from $1,806 million in 2025 . The Gross Profit Percentage was 50% in 2026, down from 54% in 2025, primarily due to fixed manufacturing costs in relation to decreased Enterprise Health sales .<h4>Operating Expenses</h4>Sales and Marketing expenses were $2,051 million in 2026, an increase of $344 million (20%) from $1,707 million in 2025, primarily due to higher bad debt expense of $298 million related to one customer . Research and Development expenses decreased by $405 million (-41%) to $583 million in 2026 from $988 million in 2025, mainly due to lower headcount and absence of severance expense . General and Administrative expenses were $4,058 million in 2026, an increase of $1,507 million (59%) from $2,551 million in 2025, primarily due to higher legal costs related to the Business Combination . An impairment loss of $89 million for a right-of-use asset was recognized in 2026 within general and administrative expenses . Total Operating Expenses were $6,692 million in 2026, an increase of $1,446 million (28%) from $5,246 million in 2025 .<h4>Operating Loss and Net Loss</h4>Loss from Operations was - $5,618 million in 2026, compared to - $3,440 million in 2025 . The Net Loss was - $6,885 million in 2026, compared to - $2,891 million in 2025 .<h4>Other (Expense) Income, Net</h4>Interest Expense, Net was - $143 million in 2026, an increase of $71 million (99%) from - $72 million in 2025 . The company reported a Loss on Revaluation of Warrant Liabilities of - $727 million in 2026, compared to a gain of $1 million in 2025 . Finance Cost Associated with Warrant Issuance was - $145 million in 2026 . Unrealized Loss on Foreign Exchange was - $239 million in 2026, compared to a gain of $626 million in 2025 . Other Expense, Net was - $13 million in 2026, compared to - $6 million in 2025 .<h4>Cash Flow Activities</h4>Net Cash Used in Operating Activities was - $2,123 million in 2026, compared to - $1,965 million in 2025, primarily due to higher legal costs, partially offset by cost savings and operating efficiencies . Net Cash Used in Investing Activities was $0 million in 2026, compared to - $10 million in 2025 . Net Cash Provided by Financing Activities was $4,952 million in 2026, primarily from $5,265 million net proceeds from the January 2026 Private Placement, partially offset by debt payments . Cash and Restricted Cash at the end of the period were $3,993 million as of March 31, 2026, compared to $8,054 million as of March 31, 2025 . Unrestricted cash as of March 31, 2026, was approximately $3,743 million .<h4>Liquidity and Material Cash Requirements</h4>Working Capital was $5,000 million as of March 31, 2026, a decrease from $5,400 million as of December 31, 2025 . Total contractual obligations as of March 31, 2026, amounted to $6,163 million, with $5,403 million due within one year . This includes a B. Riley Promissory Note of $2,400 million and a Parker Hannifin Promissory Note of $1,875 million .<h4>Strategic Focus and Outlook</h4>Ekso Bionics Holdings, Inc. prioritizes educating clinical and executive stakeholders on the economic and clinical value of its robotic exoskeleton portfolio in the Enterprise Health Market, targeting rehabilitation centers and commercial/industrial sectors . For the Personal Health Market, the company is developing its go-to-market program for Ekso Indego Personal, aiming for increased CMS reimbursement submissions and expecting Personal Health product sales to contribute more quarter over quarter in 2026, with general commercialization for Nomad anticipated in late 2026 . The company is also undergoing a Business Combination, expected to close in the second quarter of 2026, which will result in it changing its name to ChronoScale Corporation, and is exploring strategic transactions for its medical device business . Due to significant operating losses and negative cash flows, management estimates cash on hand will fund operations into early Q3 2026, and substantial doubt exists about the company’s ability to continue as a going concern without additional capital fundraising .

EKSO

EKSO Bionics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2.141 M